Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...
Hosted on MSN5d
ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinomaThomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center and director of the University ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...
There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...
Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital ...
Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than Sunitinib patients.
Patients with metastatic renal cell carcinoma staged pT1-4 Nx M1 were enrolled ... ultrasonic examinations and bone scintigraphy before and 12 week after the first immunization.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback